Numerous nanotechnology in healthcare research efforts deal with diagnosing and fighting the Human immunodeficiency virus (HIV) that causes AIDS (Acquired Immune Deficiency Syndrome). Nanotechnology offers a unique opportunity to combine and improve different pharmacological profiles of antiretroviral drugs, with more convenient drug administration and potentially better patient adherence to HIV therapy. In developing countries, where the so-called 'big three' diseases (HIV/AIDS, malaria and tuberculosis) are responsible for millions of deaths, this may also be a major part of the advantages that result from nanotechnology. Form 1 human immunodeficiency virus (HIV-1) has been one of the most lethal adult infectious diseases at present. There were nearly 2 million new cases of HIV in 2014, according to the Centers for Disease Control and Prevention (CDC). Around the world, there are about 36.9 million people living with HIV. In 2014, an estimated 1.2 million individuals died from AIDS-related diseases. And there is no cure and no preventive HIV / AIDS vaccine yet. Over nearly 30 years of research, a cure for HIV / AIDS has been elusive. Early therapies focused on antiretroviral drugs that were only to a certain degree successful. However, it was the emergence in the mid-1990s of a class of drugs known as protease inhibitors and the advent of triple-drug therapy that revolutionised the treatment of HIV / AIDS. This marked the beginning of the Highly Active Antiretroviral Therapy (HAART) period, in which a mixture of three or more separate groups of drugs are given simultaneously. Some HAART regimens, however, have significant side effects and, in all cases, HAART must be taken for a lifetime, with one or two pills taken everyday. Some patients also develop resistance to such drug formulations, resulting in therapy failure. The lack of full care under current treatment underscores the great need for continued efforts in the search for new approaches to HIV / AIDS treatment. Solid colloidal particles with sizes ranging from 10 to 1000 nm are nanoparticles. Depending on their colloidal size and polymeric composition, they are able to target drugs to established locations in the body along with their sustained release. Nanoparticles are also explored for improvement of formulation and efficacy of drugs with physico-chemical drawbacks like poor stability and solubility. They are being increasingly investigated for targeted delivery of ARVs to HIV-infected cells and to achieve sustained drug-release kinetics. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this https://www.scholarscentral.org/submissions/hiv-aids-research.html